Please assess the completion status of the following clinical trial:

Trial Title: Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult male or female ≥ 18 years of age at the time of signing the informed consent form (ICF).~2. Clinical diagnosis of acquired thrombotic thrombocytopenic purpura (aTTP) (initial or recurrent), which included thrombocytopenia and microscopic evidence of red blood cell fragmentation (e.g., schistocytes).~3. Required initiation of daily PE treatment and had received 1 PE treatment prior to randomization~4. Others as defined in the protocol~Exclusion Criteria:~1. Platelet count ≥100×10E9/L.~2. Serum creatinine level \>200 µmol/L in case platelet count is \> 30×10E9/L~3. Known other causes of thrombocytopenia~4. Congenital TTP (known at the time of study entry).~5. Pregnancy or breast-feeding.~6. Subjects who were previously enrolled in a clinical study with caplacizumab and received caplacizumab or for whom the assigned treatment arm is unknown~7. Others as defined in the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Caplacizumab (Type: EXPERIMENTAL): Caplacizumab 10 mg once daily
- Placebo (Type: PLACEBO_COMPARATOR): Placebo once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).